biostudies-literatureLone WNCI NIH HHSNational Institutes of HealthNIGMS NIH HHSNIH HHSLeukemia and Lymphoma Society10-22https://www.ebi.ac.uk/biostudies/studies/S-EPMC11625982biostudies-literatureUnknown100(1)High-grade B-cell lymphoma not otherwise specified (HGBCL, NOS) has overlapping morphological and genetic features with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL), leading to uncertainty in its diagnosis and clinical management. Using functional genomic approaches, we previously characterized HGBCL and NOS, that demonstrate gene expression profiling (GEP), and genetic signatures similar to BL. Herein, we characterize distinct HGBCL, NOS, cohort (n = 55) in adults (n = 45) and in children (n = 10), and compared the GEP, genomic DNA copy number (CN), and mutational spectrum with de novo DLBCL (n = 85) and BL (n = 52). This subgroup, representing ~60% of HGBCL, NOS, lack gene-expression signature of BL and double hit/dark zone lymphoma, but express DLBCL like signatures aAmerican journal of hematologyHigh-grade B-cell lymphoma not otherwise specified, with diffuse large B-cell lymphoma gene expression signatures: Genomic analysis and potential therapeutics.PMC11625982P30 CA036727P30 GM110768TRP-6129-04P20GM103427-14P50 CA136411P20GM103427‐14T32 CA009476T32CA009476‐23P20 GM103427P30GM110768‐01P01 CA229100P30CA036727TRP‐6129‐04P30GM110768-01UH2 CA206127T32CA009476-23U01CA157581U01 CA157581Xu AMDave BJVose JBouska AJochum DYu JIssa IILone WBi CShah ARGreiner TCHartert KAmador CMcKeithan TWBhagavathi SKHerek TAMerchant AIqbal JWeisenburger DDSharma SSaumyaranjan MSong JEl-Gamal DGreen MZhang XHeavican-Foral TBChan WCMir ARFu KAlkhinji AAfalseHigh-grade B-cell lymphoma not otherwise specified, with diffuse large B-cell lymphoma gene expression signatures: Genomic analysis and potential therapeutics.High-grade B-cell lymphoma not otherwise specified (HGBCL, NOS) has overlapping morphological and genetic features with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL), leading to uncertainty in its diagnosis and clinical management. Using functional genomic approaches, we previously characterized HGBCL and NOS, that demonstrate gene expression profiling (GEP), and genetic signatures similar to BL. Herein, we characterize distinct HGBCL, NOS, cohort (n = 55) in adults (n = 45) and in children (n = 10), and compared the GEP, genomic DNA copy number (CN), and mutational spectrum with de novo DLBCL (n = 85) and BL (n = 52). This subgroup, representing ~60% of HGBCL, NOS, lack gene-expression signature of BL and double hit/dark zone lymphoma, but express DLBCL like signatures a2025-01-01T00:00:00Z2025 Jan2025-04-03T23:55:59.856Z2025-04-03T23:55:59.856ZS-EPMC116259823954880710.1002/ajh.27513